Revon’s Mobile Software Platform and Triage Algorithms will help to further evaluate new asthma trial endpoint
Louisville, KY: Digital therapeutics company, Revon Systems will be working with AstraZeneca’s Innovative Medicine and Early Development (IMED) Biotech Unit in respiratory clinical trials to evaluate CompEx, a novel therapeutic endpoint for asthma. CompEx is an algorithm combining patient-recorded lung function deterioration, symptoms and use of reliever medication with the traditional measurement of severe exacerbations.
Dr. Sumanth Swaminathan, Chief Data Scientist, Revon Systems said, “This is a great opportunity for Revon to leverage its triage algorithms and clinical trials platform in a respiratory trial. AstraZeneca has an exciting pipeline of investigational asthma therapies, and we are delighted to be partnering with them in this effort to transform asthma exacerbation trials.”
Dr. Carla A Da Silva, Director of Clinical Research, AstraZeneca said, “By using Revon’s technology we are able to conduct real-time assessments of CompEx events. We are eager to evaluate how these correlate with patient health escalations, medication usage, and Revon’s machine-learned triage prediction.”
In this collaboration, AstraZeneca’s clinical trial infrastructure will integrate with Revon’s Smart Symptom Trackers to help accelerate the development of novel respiratory therapies in clinical trials. Initially, Revon will provide its software platform and conduct real-time data analysis for one trial in Phase 2. Revon will also provide device support and training for enrolling patients onto the platform.
About Revon Systems: REVON is a digital therapeutics company that enables patients to self-manage their asthma and COPD signs and symptoms. REVON has a built-in machine learning feature called a Smart Symptom Tracker that helps patients interpret troubling symptoms and signs with the goal of finding the right level of care earlier in their illness.